Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis

Core Insights - Rein Therapeutics has initiated the first patient dosing in its Phase 2 clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis (IPF), a severe lung disease with limited treatment options [1][4] Company Overview - Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications [7] - The lead product candidate, LTI-03, is a synthetic peptide designed to mimic Caveolin-1, aiming to regulate multiple fibrosis pathways and support lung function [6][7] Clinical Trial Details - The Phase 2 trial is a randomized, double-blind, placebo-controlled study involving approximately 120 patients across multiple countries, with interim data expected in the second half of 2026 [2][3] - The trial will assess safety, tolerability, and changes in lung function, specifically measuring forced vital capacity (FVC) [3] Market Context - IPF affects around 100,000 individuals in the U.S. annually, characterized by lung tissue scarring and a median survival of three to five years post-diagnosis [5]